|Articles|September 12, 2016

NoroCORE and the Perfect Pathogen: USDA-NIFA Efforts to Control Norovirus

Dubbed 'the perfect pathogen' by researchers, norovirus possesses all the markers of an ideal infectious agent.

Dubbed ‘the perfect pathogen’ by researchers, norovirus possesses all the markers of an ideal infectious agent. It is “highly contagious” and “moderately virulent,” which allows most of those who are infected to fully recover. The virus frequently sheds and continually evolves, and everyone is susceptible to infection.

Evidence has demonstrated that a targeted vaccine intervention may be necessary to reduce norovirus disease and prevent outbreaks. Although a vaccine may one day serve as another critical tool, it must be noted that thorough epidemiologic investigations and sound infection control practices will still undoubtedly continue to be necessary in curtailing the spread of these well-adapted pathogens.

Norovirus is the leading cause of food-borne illness in the United States, with 5 million of the reported 21 million annual cases linked to contaminated foods. The cost of illness is estimated to be billions of dollars per year.

In developing countries where the greatest amount of diarrheal disease occurs, norovirus is estimated to cause upwards of 200,000 deaths annually in children under five years of age. In order to address the burden of norovirus disease, scientists and other public health professionals must first understand the way in which the virus spreads.

The Norovirus Collaborative for Outreach, Research, and Education (NoroCORE), led by North Carolina State University, is a multi-disciplinary collaborative food safety initiative that is comprised of 30 researchers and top scientists in the field of basic food and environment virology from 25 universities. NoroCore is determined to reduce food-borne disease associated with viruses, particularly, noroviruses.

The United States Department of Agriculture’s (USDA) National Institute of Food Agriculture (NIFA) supports the project, which began back in 2011, with a $25 million, 6-year Agriculture and Food Research initiative grant.

The six primary objectives of NoroCORE are available on the official website.

According to the website, the “researchers designed the project with a ‘new biology’ approach to science in mind,” one that consists of interdisciplinary collaborative efforts. With input from more than 200 stakeholders, including members of government, food production and safety groups, restaurant and cruise line industries, and testing laboratories, collaborators work, across institutes and disciplines, to develop better tools and skills as well as share resources and knowledge.

NoroCORE team members regularly publish results in a number of peer-reviewed journals which makes research accessible, available, and immediately applicable to real-world needs. In addition, a key feature of NoroCORE is a commitment to education and outreach.

According to NoroCORE, “Significant progress has been made to-date, with most of the “ground work” set and critical mass met for even greater strides over the coming years. Longer-term goals, such as many of the activities in the Prevention & Control and Extension and Education Cores, will begin to be realized in the latter years of the project based on the research advances made to date, and the groundwork now being laid for these activities.”


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.